Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40256-020-00431-z http://scihub22266oqcxt.onion/10.1007/s40256-020-00431-z 32748336!7398761!32748336     free     free     free       Am+J+Cardiovasc+Drugs 2020 ; 20 (5): 393-403 Nephropedia Template TP {{tp|p=32748336|t=2020. Current Overview on Hypercoagulability in COVID-19 |pdf=|usr=}}{{32748336}} gab.com Text Current Overview on Hypercoagulability in COVID-19 JO: Am J Cardiovasc Drugs http://www.kidney.de/pget.php?&tw=1&pmid=32748336 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought many unique pathologies, such as coagulopathy, prompting a desperate need for effective management. COVID-19-associated coagulopathy (CAC) can cause various thromboembolic complications, especially in critically ill patients. The pathogenesis is likely due to endothelial injury, immobilization, and an increase in circulating prothrombotic factors. Data on treatment are limited, although prophylactic anticoagulation is advised in all hospitalized patients. Herein, we have comprehensively reviewed the current literature available on CAC and highlight the pathogenesis, clinical features, and management of CAC. Twit Text FOAVip Current Overview on Hypercoagulability in COVID-19 ????Am J Cardiovasc Drugs http://www.kidney.de/pget.php?&tw=1&pmid=32748336 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32748336 #FOAvip English Wikipedia <ref>{{Cite pmid|32748336}}</ref> Current Overview on Hypercoagulability in COVID-19 #MMPMID32748336 Singhania N; Bansal S; Nimmatoori DP; Ejaz AA; McCullough PA; Singhania G Am J Cardiovasc Drugs 2020[Oct]; 20 (5): 393-403 PMID32748336show ga The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought many unique pathologies, such as coagulopathy, prompting a desperate need for effective management. COVID-19-associated coagulopathy (CAC) can cause various thromboembolic complications, especially in critically ill patients. The pathogenesis is likely due to endothelial injury, immobilization, and an increase in circulating prothrombotic factors. Data on treatment are limited, although prophylactic anticoagulation is advised in all hospitalized patients. Herein, we have comprehensively reviewed the current literature available on CAC and highlight the pathogenesis, clinical features, and management of CAC. |*Blood Coagulation Disorders/etiology/physiopathology/prevention & control[MESH] |*Coronavirus Infections/blood/epidemiology/therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/blood/epidemiology/therapy[MESH] |*Thrombophilia/drug therapy/virology[MESH] |Betacoronavirus/physiology[MESH] |COVID-19[MESH] |Chemoprevention/*methods[MESH] |Hematologic Agents/*pharmacology[MESH] |Humans[MESH]Current Overview on Hypercoagulability in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing